This article's lead is ready for translation. Click for more information.

Terlipressin

From WikiProjectMed
Jump to navigation Jump to search
Terlipressin
Names
Trade namesTeripress, Glypressin, Terlivaz, others
Other namesTerlipressin acetate, triglycyl lysine vasopressin
  • 1-{[(4R,7S,10S,13S,16S,19R)-19-{[({[(aminoacetyl)amino]acetyl}amino)acetyl]amino}-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}-L-prolyl-N-(2-amino-2-oxoethyl)-L-lysinamide
Clinical data
Drug classVasopressin analog[1]
Main usesEsophageal varices, hepatorenal syndrome[2][3]
Side effectsAbdominal pain, nausea, respiratory failure, diarrhea[3]
Routes of
use		IV
External links
AHFS/Drugs.comMonograph
Pharmacokinetics
Protein binding~30%
Chemical and physical data
FormulaC52H74N16O15S2
Molar mass1227.38 g·mol−1
3D model (JSmol)
  • O=C(N)CNC(=O)[C@@H](NC(=O)[C@H]4N(C(=O)[C@H]1NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1)Cc2ccc(O)cc2)Cc3ccccc3)CCC(=O)N)CC(=O)N)CCC4)CCCCN
  • InChI=1S/C52H74N16O15S2/c53-17-5-4-9-31(45(76)60-23-41(57)72)63-51(82)38-10-6-18-68(38)52(83)37-27-85-84-26-36(61-44(75)25-59-43(74)24-58-42(73)22-54)50(81)65-34(20-29-11-13-30(69)14-12-29)48(79)64-33(19-28-7-2-1-3-8-28)47(78)62-32(15-16-39(55)70)46(77)66-35(21-40(56)71)49(80)67-37/h1-3,7-8,11-14,31-38,69H,4-6,9-10,15-27,53-54H2,(H2,55,70)(H2,56,71)(H2,57,72)(H,58,73)(H,59,74)(H,60,76)(H,61,75)(H,62,78)(H,63,82)(H,64,79)(H,65,81)(H,66,77)(H,67,80)/t31-,32-,33-,34-,35-,36-,37-,38-/m0/s1 checkY
  • Key:BENFXAYNYRLAIU-QSVFAHTRSA-N checkY

Terlipressin, sold under the brand names Teripress among others, is a medication used to treat bleeding esophageal varices and kidney problems in hepatorenal syndrome.[2][3] In these conditions it decreases the risk of death.[4] It is given by injection into a vein.[3]

Common side effects include abdominal pain, nausea, respiratory failure, and diarrhea.[3] Other side effects may include mesenteric ischemia and heart ischemia.[3] Use during pregnancy may harm the baby.[3] It is a vasopressin receptor activator.[3]

Terlipressin has been in medical use in various parts of the world since 1975.[4] It was approved for medical use in the United States in 2022.[3] In the United Kingdom it costs the NHS about £18 for 1 mg vial as of 2021.[2]

Medical use

Indications for use include hepatorenal syndrome,[5] and to treat bleeding esophageal varices.[6]

It has been studied for norepinephrine-resistant septic shock.[7][4] And it may also helps prevent urination.[8] Though is believed to have less of these two effects than vasopressin.[2]

Dosage

For esophageal varices it is used at a dose of 1 to 2 mg initially.[2] This may be repeated every 4 to 6 hours for 48 to 72 hours depending on the formulation.[2]

Side effects

Ischemic bowel necrosis due to terlipressin

Other possible side effects of this medication, though rare, are:[9]

  • Difficulty breathing
  • Chest pain (angina)
  • Irregular heart beats
  • Necrosis

Pregnancy

Terlipressin should not be used during pregnancy.

Society and culture

Availability

Terlipressin is not available in Canada,[10] but it is available in New Zealand,[11] Australia, much of Europe,[12] India, Pakistan & UAE.

See also

References

  1. ↑ Srivastava, Ved (22 June 2017). Peptide-based Drug Discovery: Challenges and New Therapeutics. Royal Society of Chemistry. p. 187. ISBN 978-1-78801-171-6. Archived from the original on 14 December 2022. Retrieved 14 December 2022.
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 98. ISBN 978-0857114105.
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 "DailyMed - TERLIVAZ- terlipressin injection, powder, lyophilized, for solution". dailymed.nlm.nih.gov. Archived from the original on 28 September 2022. Retrieved 12 December 2022.
  4. ↑ 4.0 4.1 4.2 Kulkarni, Anand V.; Arab, Juan Pablo; Premkumar, Madhumita; Benítez, Carlos; Tirumalige Ravikumar, Sowmya; Kumar, Pramod; Sharma, Mithun; Reddy, Duvvuru Nageshwar; Simonetto, Douglas A.; Rao, Padaki Nagaraja (December 2020). "Terlipressin has stood the test of time: Clinical overview in 2020 and future perspectives". Liver International. 40 (12): 2888–2905. doi:10.1111/liv.14703.
  5. ↑ Uriz J, Ginès P, Cárdenas A, Sort P, Jiménez W, Salmerón J, Bataller R, Mas A, Navasa M, Arroyo V, Rodés J (2000). "Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome". J Hepatol. 33 (1): 43–8. doi:10.1016/S0168-8278(00)80158-0. PMID 10905585.
  6. ↑ Ioannou G, Doust J, Rockey D (2003). Ioannou GN (ed.). "Terlipressin for acute esophageal variceal hemorrhage". Cochrane Database Syst Rev (1): CD002147. doi:10.1002/14651858.CD002147. PMC 7017851. PMID 12535432.
  7. ↑ O'Brien A, Clapp L, Singer M (2002). "Terlipressin for norepinephrine-resistant septic shock". Lancet. 359 (9313): 1209–10. doi:10.1016/S0140-6736(02)08225-9. PMID 11955542. S2CID 38463837.
  8. ↑ Kam, P. C. A.; Williams, S.; Yoong, F. F. Y. (2004). "Vasopressin and terlipressin: pharmacology and its clinical relevance". Anaesthesia. 59 (10): 993–1001. doi:10.1111/j.1365-2044.2004.03877.x. ISSN 1365-2044. PMID 15488059. S2CID 26849892.
  9. ↑ "TERLIPRESSIN ACETATE 1 MG SOLUTION FOR INJECTION". Drugs.com. Archived from the original on 26 June 2019. Retrieved 16 December 2021.
  10. ↑ "Drug Product Search". Archived from the original on 2008-07-14.
  11. ↑ "Archive copy" (PDF). Archived (PDF) from the original on 2021-12-20. Retrieved 2021-12-02.{{cite web}}: CS1 maint: archived copy as title (link)
  12. ↑ "Terlipressin". Archived from the original on 2019-06-26. Retrieved 2021-12-02.

External links

Identifiers:

Retrieved from "https://mdwiki.org/w/index.php?title=Terlipressin&oldid=1456925"